MedTrace Logo

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 406

Last updated 2026-04-20

Study results available
· View outcomes & findings →

Summary

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

Conditions

  • Immunoglobulin A Nephropathy

Interventions

DRUG

sparsentan

Target dose of 400 mg daily

DRUG

irbesartan

Target dose of 300 mg daily

DRUG

Dapagliflozin

Target dose of 10 mg daily

Sponsors & Collaborators

  • Travere Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Radko Komers, MD, PhD · Travere Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-11
Primary Completion
2023-08-07
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Croatia
  • Czechia
  • Estonia
  • France
  • Germany
  • Hong Kong
  • Italy
  • Lithuania
  • New Zealand
  • Poland
  • Portugal
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03762850 on ClinicalTrials.gov